MALAT1 and Familial prostate cancer: MALAT1-silenced prostate cancer cells exhibited decreased cell proliferation compared with shSCRM cells, while the effect was more pronounced (∼80%) in olaparib-treated cells (Fig. 6B), indicating that MALAT1 depletion augments olaparib activity.